DYN – dyne therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors [Yahoo! Finance]
Dyne Therapeutics: 2026 Catalysts Point To Further Upside [Seeking Alpha]
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $16.00. They now have a "neutral" rating on the stock.
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Form 8-K Dyne Therapeutics, Inc. For: Jan 12
Form SCHEDULE 13G Dyne Therapeutics, Inc. Filed by: T. Rowe Price Investment Management, Inc.
Form 4 Dyne Therapeutics, Inc. For: Dec 22 Filed by: Karnani Vikram
Form 3 Dyne Therapeutics, Inc. For: Dec 22 Filed by: Karnani Vikram
Form 8-K Dyne Therapeutics, Inc. For: Dec 22
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.